ELOX Stock Forecast & Price Target

Eloxx Pharma is compelling because exaluren targets the root cause of nonsense-mutation kidney disease by promoting ribosomal readthrough, and it has already shown a clean safety profile across 145 subjects in 8 early-stage trials with no dose-limiting toxicity or nephrotoxicity. The lead Alport study, EXACT, is a 24-patient, 32-week Phase 2b that began dosing in September, following Phase 2a evidence in 3 patients where collagen IV rose in all three and filtration slit density improved ~50% over 8 weeks, supporting proof of mechanism. Fundamentally, the market appears to underappreciate the program’s risk-adjusted value, with an rNPV around $44.74/sh versus a market capitalization near $139M, while cash of about $62M and no debt should fund operations into mid-2028 through both major readouts.

Eloxx Pharma is viewed negatively because its lead programs remain early-stage and are supported by very small datasets, making efficacy hard to validate and leaving major uncertainty around placebo response, endpoint variability, and the durability of any pharmacodynamic effect. In Alport, the company still must prove that filtration slit density correlates with proteinuria and eGFR, while the 16-week study needs a meaningful FSD signal and roughly a 40% uPCR decline to look convincing, a hurdle that appears difficult; in ADPKD, the biology risk is even greater because readthrough, protein folding, and tissue delivery remain unresolved. Financially, it had about $62 million in cash, cash equivalents, and marketable securities at the end of 2Q 2026, but with no expectation of profitability until 2033 and a reliance on future capital raises, dilution risk remains high.